Teva’s topsy-turvy legal battle over potential damages stemming from the labelling and use of its generic of GlaxoSmithKline’s Coreg (carvedilol) antihypertensive has swung back the other way, with a split US Court of Appeals reinstating a finding of infringement and a $235m damage award from 2017 against the Israeli firm.
The appeals panel has reversed a finding by a Delaware district court that the Israeli firm did not induce infringement...








